Eribulin monotherapy versus treatment of physician's choice in patients with metastatic breast cancer (EMBRACE): a phase 3 open-label randomised studyJavier Cortés, Chris Twelves, Linda T. Vahdat et al.|The Lancet|2011Cited by 1.1k
Phase II Study of Eribulin Mesylate, a Halichondrin B Analog, in Patients With Metastatic Breast Cancer Previously Treated With an Anthracycline and a TaxaneLinda T. Vahdat, Joanne L. Blum, Brian Pruitt et al.|Journal of Clinical Oncology|2009Cited by 245